The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD
Open accessAbstract
Vascular endothelial growth factor (VEGF) is a key mediator in the development and progression of choroidal neovascularization (CNV) in patients with wet age-related macular degeneration (AMD). As a consequence, current treatment strategies typically focus on the administration of anti-VEGF agents, such as Aflibercept (Eylea), that inhibit VEGF function. While this approach is largely successful at counteracting CNV progression, the treatment can require repetitive (i.e. monthly) intravitreal injections of the anti-VEGF agent throughout the patient’s lifetime, imposing a substantial financial and medical burden on the patient. Moreover, repetitive injection of anti-VEGF agents over a period of years may encourage progression of retinal and choroidal atrophy in patients with AMD, leading to a decrease in visual acuity. Herein, we have developed a single-injection recombinant adeno-associated virus (rAAV)-based gene therapy treatment for wet AMD that prevents CNV formation through inducible over-expression of Eylea. First, we demonstrate that by incorporating riboswitch elements into the rAAV expression cassette allows protein expression levels to be modulated in vivo through oral supplementation on an activating ligand (e.g. tetracycline). We subsequently utilized this technology to modulate the intraocular concentration of Eylea following rAAV delivery, leading to nearly complete (p = 0.0008) inhibition of clinically significant CNV lesions in an established mouse model of wet AMD. The results shown in this study pave the way for the development of a personalized gene therapy strategy for the treatment of wet AMD that is substantially less invasive and more clinically adaptable than the current treatment paradigm of repetitive bolus injections of anti-VEGF agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Effect of intraocular Eylea concentration on CNV lesion formation in a murine model of wet AMD. Leakage from CNV lesions was assessed 7 days following laser injury. Representative FA images taken 5 minutes after fluorescein injection for mice injected with either (A–C) rAAV2[MAX].smCBA-Eylea, (D–F) rAAV2[MAX].smCBA-Eylea-1×-TC45 + standard diet, (G–I) rAAV2[MAX].smCBA-Eylea-1×-TC45 + tetracycline diet or (J–L) PBS (n = 16–20 lesions per group). Images of 3 mice per group with red arrows indicating site of the laser injury. (M) Distribution of lesions graded independently by three masked scientists. n = 16–20 lesions per group, p < 0.0001, Chi-squared test. (N) Intraocular levels of non-complexed Eylea assayed by ELISA. n = 5 eyes per group, standard error displayed.](https://figures.cochat.ai/paper-figures/f08baf5b91a947da84a32d35acee5324/development-of-an-inducible-anti-vegf-raav-gene-therapy-strategy-for-the-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Riboswitches have gained considerable attention for rAAV ocular therapies because of their small size (100 bp cis-acting RNA sequence), adaptability to ligands, and the development of synthetic riboswitches [173,178,179].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [179]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, Reid et al. illustrated the functional viability of an inducible transgene system in a murine model of wet AMD (Reid et al., 2018) while others have demonstrated its capability in IRDs (Lh ´ eriteau et al., 2010).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Reid et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Bird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926
Ghasemi Falavarjani, K., & Nguyen, Q. D. (2013) · Eye · doi:10.1038/eye.2013.107 · Cited by 982
Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis
Chakravarthy, U., Wong, T. Y., Fletcher, A., Piault, E., Evans, C., Zlateva, G., Buggage, R., Pleil, A., & Mitchell, P. (2010) · BMC Ophthalmology · doi:10.1186/1471-2415-10-31 · Cited by 842
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines
Agwuh, K. N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl224 · Cited by 806
Nishijima, K., Ng, Y.-S., Zhong, L., Bradley, J., Schubert, W., Jo, N., Akita, J., Samuelsson, S. J., Robinson, G. S., Adamis, A. P., et al. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.061237 · Cited by 707
Riboswitches and the RNA World
Breaker, R. R. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003566 · Cited by 666
Krzystolik, M. G. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.3.338 · Cited by 590 · cited 1×
“Lesion images from all groups were collated and randomized before being independently graded by three masked reviewers using the system described by Krzystolik et al., 2002 (See Supplemental Fig.”
MethodAttenuation of green fluorescent protein half-life in mammalian cells
Corish, P., & Tyler-Smith, C. (1999) · Protein Engineering, Design and Selection · doi:10.1093/protein/12.12.1035 · Cited by 559
FUNDUS AUTOFLUORESCENCE IMAGING: Review and Perspectives
SCHMITZ-VALCKENBERG, S., HOLZ, F. G., BIRD, A. C., & SPAIDE, R. F. (2008) · Retina · doi:10.1097/iae.0b013e318164a907 · Cited by 537
Cited by
Update on Retinal Vein Occlusion
Romano, F., Lamanna, F., Gabrielle, P., Teo, K. Y. C., Parodi, M. B., Iacono, P., Fraser‐Bell, S., Cornish, E. E., Nassisi, M., Viola, F., et al. (2023) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000598 · Cited by 131
Engineering synthetic RNA devices for cell control
Dykstra, P. B., Kaplan, M., & Smolke, C. D. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00436-7 · Cited by 133
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
Brinks, J., van Dijk, E. H. C., Klaassen, I., Schlingemann, R. O., Kiełbasa, S. M., Emri, E., Quax, P. H. A., Bergen, A. A. B., Meijer, O. C., & Boon, C. J. F. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100994 · Cited by 88
The Theophylline Aptamer: 25 Years as an Important Tool in Cellular Engineering Research
Wrist, A., Sun, W., & Summers, R. M. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00475 · Cited by 72
Metadata
- Authors
- Reid, C. A., Nettesheim, E. R., Connor, T. B., & Lipinski, D. M.
- Affiliations
- Medical College of Wisconsin (US)
- Corresponding author
- Lipinski, Daniel M.
- Venue
- Scientific Reports
- Published
- 2018-08-06
- Volume
- 8
- Issue
- 1
- Pages
- 11763-11763
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC6079038
- OpenAlex
- W2887127418
- Cited by
- 65
- References
- 49
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 8 · 2023: 12 · 2022: 11 · 2021: 8 · 2020: 8 · 2019: 6
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Eye Institute (P30 EY001931-37)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- neovascular age-related macular degeneration, choroidal neovascularization, recombinant adeno-associated virus, aflibercept, riboswitches, inducible gene expression, tetracycline, intravitreal gene delivery
- MeSH terms
- Dependovirus, Animals, Enzyme-Linked Immunosorbent Assay, Female, Humans, Mice, Inbred C57BL, Software, Genetic Therapy, Microscopy, Confocal, Choroidal Neovascularization, Vascular Endothelial Growth Factor A, Mice, Wet Macular Degeneration, HEK293 Cells, Riboswitch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD. https://app.cochat.ai/papers/10.1038/s41598-018-29726-7
- The paper
- Reid, C. A., Nettesheim, E. R., Connor, T. B., & Lipinski, D. M. (2018). Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD. Scientific Reports. https://doi.org/10.1038/s41598-018-29726-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.